Risdiplam (Evrysdi™). HTA ID: 21006
Risdiplam (Evrysdi™) is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.
| NCPE Assessment Process | Ongoing |
| Rapid review commissioned | 15/03/2021 |
| Rapid review completed | 29/03/2021 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of risdiplam compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by the HSE | 04/05/2021 |
| Pre-submission consultation with Applicant | 28/06/2021 |
| Full HTA submission received from Applicant | 20/08/2021 |
| Current Status | NCPE assessment ongoing |